GlassScriptPhysician profile
So Yeon Chung
NPI 1225423254
$631.47
in general payments reported to CMS, 2019-2025
13 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.94 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.80 | 2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $74.15 | 2025 | |
| Lilly USA, LLC | $51.82 | 2025 | Zepbound |
| Xeris Pharmaceuticals, INC. | $32.05 | 2025 | Gvoke Hypopen |
| Antares Pharma, INC. | $26.11 | 2025 | Xyosted |
| Kyowa Kirin, INC. | $21.07 | 2025 | |
| Endo USA, INC. | $19.91 | 2025 | Aveed |
| Rhythm Pharmaceuticals, INC. | $18.83 | 2025 | Imcivree |
| Corcept Therapeutics | $18.31 | 2025 | Korlym |
| Stemline Therapeutics INC. | $16.94 | 2020 | |
| Tolmar, INC. | $14.83 | 2025 | Jatenzo |
| Acella Pharmaceuticals, LLC | $14.38 | 2025 | NP Thyroid 60 |
| Glaxosmithkline, LLC. | $14.27 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw So Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.